Business
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE)
About this update from Aclaris Therapeutics, Inc.
[{"type":"text","content":"Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update. “We have continued to progress our clinical programs, including activating multiple clinical sites in our Phase 2b trial of ATI-1777 in subjects with moderate to severe atopic dermatitis,” said Dr. Neal Walker, President and CEO of Aclaris. “We look forward to advancing all of our clinical and preclinical programs.” Research and Development Highlights: Clinical Programs Zunsemetinib, an investigational oral small molecule MK2 inhibitor:Currently being developed as a potential treatment for immuno-inflammatory diseases ATI-450-RA-202: This Phase 2b dose ranging trial to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses (20 mg and 50 mg twice daily) of zunsemetinib in combination with methotrexate in subjects with moderate to severe rheumatoid arthritis (RA) is ongoing. Aclaris expects topline data in 2023. ATI-450-HS-201: This Phase 2a trial to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of zunsemetinib (50 mg twice daily) in subjects with moderate to severe hidradenitis suppurativa (HS) is ongoing. Aclaris expects topline data in the first half of 2023. ATI-450-PsA-201: Aclaris expects to activate clinical sites in the coming weeks in this Phase 2a trial of zunsemetinib (50 mg twice daily) in subjects with moderate to severe psoriatic arthritis. ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor:Currently being developing as a potential treatment for moderate to severe atopic dermatitis (AD) ATI-1777-AD-202: Aclaris activated multiple clinical sites in May 2022 in this Phase 2b trial to determine the efficacy, safety, tolerability and pharmacokinetics of ATI-1777 in subjects with moderate to severe AD. In this trial, Aclaris will explore multiple concentrations of twice daily treatment with ATI-1777 and a single concentration of once daily treatment with ATI-1777, in patients 12 years and old...